Juan Antonio Santos Miranda
Complutense University of Madrid
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Juan Antonio Santos Miranda.
International Journal of Radiation Oncology Biology Physics | 2012
Javier Pascau; Juan Antonio Santos Miranda; Felipe A. Calvo; Ana Bouché; Virgina Morillo; Carmen González San Segundo; Carlos Ferrer; Juan López Tarjuelo; Manuel Desco
PURPOSE Intraoperative electron beam radiation therapy (IOERT) involves a modified strategy of conventional radiation therapy and surgery. The lack of specific planning tools limits the spread of this technique. The purpose of the present study is to describe a new simulation and planning tool and its initial evaluation by clinical users. METHODS AND MATERIALS The tool works on a preoperative computed tomography scan. A physician contours regions to be treated and protected and simulates applicator positioning, calculating isodoses and the corresponding dose--volume histograms depending on the selected electron energy. Three radiation oncologists evaluated data from 15 IOERT patients, including different tumor locations. Segmentation masks, applicator positions, and treatment parameters were compared. RESULTS High parameter agreement was found in the following cases: three breast and three rectal cancer, retroperitoneal sarcoma, and rectal and ovary monotopic recurrences. All radiation oncologists performed similar segmentations of tumors and high-risk areas. The average applicator position difference was 1.2 ± 0.95 cm. The remaining cancer sites showed higher deviations because of differences in the criteria for segmenting high-risk areas (one rectal, one pancreas) and different surgical access simulated (two rectal, one Ewing sarcoma). CONCLUSIONS The results show that this new tool can be used to simulate IOERT cases involving different anatomic locations, and that preplanning has to be carried out with specialized surgical input.
Clinical & Translational Oncology | 2005
Carmen González San Segundo; Felipe A. Calvo Manuel; Juan Antonio Santos Miranda
ResumenAdministrar la dosis prescrita en el tiempo programado, sin retrasos en el inicio ni interrupciones en su ejecución, es un objetivo fundamental en los tratamientos conradioterapia (RT). En algunas localizaciones tumorales, se ha objetivado su influencia pronóstica en el control local y en la evolución de los pacientes.El presente estudio analiza las causas de los retrasos en el inicio de la RT así como, una vez iniciado el tratamiento, los principales motivos que prolongan la irradiación. En la revisión de la literatura realizada, los cánceres de cabeza y cuello, cérvix, mama y pulmón, parecen ser los más “perjudicados” por las interrupciones o demoras en la administración de la dosis total programada.En el caso del retraso en el inicio, se mencionan como las principales causas de demora: las listas de espera, la falta de recursos y la complejidad de los tratamientos actuales de RT. El inicio tan precoz como sea posible, en los tratamientos radicales y paliativos, y el intervalo de 6–8 semanas, en los tratamientos complementarios, son las recomendaciones recogidas en la mayoría de los estudios.Las interrupciones durante el tratamiento incluyen las paradas técnicas previstas para el mantenimiento programado de las unidades, que suponen el 60%, así como las producidas por toxicidad y averías. La influencia de las mismas, según el momento y la localización tumoral, así como los mecanismos para compensar la prolongación del tiempo total de tratamiento, completan la revisión bibliográfica llevada a cabo en este trabajo.AbstractPrescribed total radiation dose should be administered within in a specific time-frame and delays in commencing treatment and/or unplanned interruptions in radiation delivery are unacceptable because, in certain cancer sites, treatment-time prolongation can have a deleterious effect on local tumour control, and on patient outcomes.The present review evaluated the causes of initial treatment delays as well as interruptions in the scheduled radiotherapy. The literature search high-lighted a significant concern in avoiding treatment-time prolongation in head and neck, cervix, breast and lung cancer.Among the causes involved in delay in radiotherapy commencement factors such as waiting lists, lack of material and human resources, and an increase complexity in planning, simulation and verification are highlighted. Most authors recommend radiotherapy commencement as soon as possible in radical (exclusive irradiation with active tumour present) and palliative situations with a maximum delay of no more than 6 to 8 weeks in the case of adjuvant radiotherapy (post-resection) programs.Interruptions during the course of treatment include: planned unit maintenance and servicing, acute patient toxicity or unexpected malfunction of linear accelerators; this last feature has the most deleterious effect on patients as well as radiotherapy practitioners. Interruptions that impact on the programmed time-course for radiotherapy needs to be compensated-for so as assure the biological equivalence in treatment efficacy with respect to cancer site and stage.Prescribed total radiation dose should be administered within in a specific time-frame and delays in commencing treatment and/or unplanned interruptions in radiation delivery are unacceptable because, in certain cancer sites, treatment-time prolongation can have a deleterious effect on local tumour control, and on patient outcomes. The present review evaluated the causes of initial treatment delays as well as interruptions in the scheduled radiotherapy. The literature search highlighted a significant concern in avoiding treatment-time prolongation in head and neck, cervix, breast and lung cancer. Among the causes involved in delay in radiotherapy commencement factors such as waiting lists, lack of material and human resources, and an increase complexity in planning, simulation and verification are highlighted. Most authors recommend radiotherapy commencement as soon as possible in radical (exclusive irradiation with active tumour present) and palliative situations with a maximum delay of no more than 6 to 8 weeks in the case of adjuvant radiotherapy (post-resection) programs. Interruptions during the course of treatment include: planned unit maintenance and servicing, acute patient toxicity or unexpected malfunction of linear accelerators; this last feature has the most deleterious effect on patients as well as radiotherapy practitioners. Interruptions that impact on the programmed time-course for radiotherapy needs to be compensated-for so as assure the biological equivalence in treatment efficacy with respect to cancer site and stage.
Clinical & Translational Oncology | 2006
Carmen González San Segundo; Juan Antonio Santos Miranda
The patient’s right to be informed has been universally recognized and reflected in the legal system of many countries. This right to correct and complete information on behalf of the patient and his admission to proceed with the recommended diagnostic or therapeutic procedure is formalized in the document commonly known as informed consent. Although the legal and bioethical considerations regarding this document have been exhaustively discussed and consensuated, its content continues to create certain doubts and uncertainties. The formal content and the manner in which the consent is obtained are the most difficult aspects.In this article, we analyze what should be included in the written informed consent, with regard to the totality of the information which the patient receives, who should inform, and how the consent should be obtained, as well as how to reflect the different aspects of the variety of radiotherapeutic procedures in the informed consent.
Archivos españoles de urología | 2007
Mª Victoria de Torres Olombrada; Carmen González San Segundo; Juan Antonio Santos Miranda; Carmen Ibáñez Villoslada; Juan Ignacio Martínez Salamanca; Felipe Herranz Amo; Felipe A. Calvo Manuel
Resumen es: Objetivo: Recientemente se han comunicado firmes evidencias por la EORTC (European Organisation for Research and Treatment of Cancer - ensayo 22911) y el...
Clinical & Translational Oncology | 2002
Carmen González San Segundo; M. Antonia Saornil Álvarez; Gonzalo Blanco Meteos; Juan Antonio Santos Miranda; Francisco López-Lara Martín
ResumenEl melanoma de coroides con afectación extraescleral representa aproximadamente el 4%–10% de los melanomas uveales. Constituye un reconocido factor pronóstico adverso, tanto para la recurrencia local como para la supervivencia global. La enu-cleación asociada a la resección quirúrgica de la extensión extraescleral es el tratamiento de elección, aunque los pobres resultados obtenidos con el tratamiento quirúrgico aislado han animado a la búsqueda de tratamientos complementarios a la cirugía. Se presenta la experiencia del Hospital Universitario de Valladolid en el tratamiento de 6 casos de melanoma con afectación extraescleral tratados con radioterapia preenucleación, analizando los resultados obtenidos, los cambios radioinducidos y la similitud con los casos publicados en la literatura.AbstractExtrascleral extension is present in 4%–10% of uveal melanomas. Its a relevant risk factor for local recur-rence and survival. Enucleation with surgical resection of the extrascleral extension is the treatment of choice. The poor results obtained with isolated surgery, have encouraged to search adjunctive treatments. We present the experience of the University Hospital of Valladolid in the treatment of 6 cases of uveal melanoma with extrascleral extension treated with pre-enucleation radiotherapy. We analize the results, the histopathologic findings induced in the enucleated eyes and the cases published in the literature.
Archivos españoles de urología | 2012
Carmen González San Segundo; Juan Antonio Santos Miranda; Alejandra Álvarez González
Clinical & Translational Oncology | 2005
Carmen González San Segundo; Felipe A. Calvo Manuel; Juan Antonio Santos Miranda
Todo hospital | 2005
Carmen González San Segundo; Juan Antonio Santos Miranda; Felipe A. Calvo Manuel; Rafael Herranz Crespo
Clinical & Translational Oncology | 2005
Carmen González San Segundo; Felipe A. Calvo Manuel; Juan Antonio Santos Miranda
Clinical & Translational Oncology | 2003
Carlos Centeno Cortés; Alvaro Sanz Rubiales; Juan Antonio Santos Miranda; Juan Manuel Núñez Olarte